Skip to main content

NCT00236444 - Risperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders

Risperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders


Data Specification

Annotated CRF

Available upon data request approval

Product Info

Generic Name
Risperidone
Product Name
RISPERDAL CONSTA®
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
375
% Female
13.0%
% White
87.0%
Product Class
Atypical Antipsychotics
Sponsor Protocol Number
CR002020 (RIS-INT-79)
Data Partner
Johnson & Johnson
Condition Studied
Attention Deficit and Disruptive Behavior Disorders
Mean/Median Age (Years)
11.1

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.